ImmunityBio, Inc. (IBRX) is a publicly traded company in the Unknown sector. Across all available filings, 13 corporate insiders have executed 87 transactions totaling $5.5M, demonstrating a bearish sentiment with -$4.9M in net insider flow. The most recent transaction on Feb 23, 2026 involved a sale of 165,000 shares valued at $1.7M.
No significant insider buying has been recorded for IBRX in the recent period.
No significant insider selling has been recorded for IBRX in the recent period.
Based on recent SEC filings, insider sentiment for IBRX is bearish with an Insider Alignment Score of 6/100 and a net flow of -$4.9M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at ImmunityBio, Inc. (IBRX) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 13 insiders are actively trading IBRX stock, having executed 87 transactions in the past 90 days. The most active insider is Capital, Llc Nant (Executive), who has made 3 transactions totaling $103.4M.
Get notified when executives and directors at IBRX file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 23, 2026 | J. Simon Barry | Executive | Sale | 165,000 | $10.25 | $1.7M | Large |
| Feb 23, 2026 | Selecky Christobel | Executive | Option Exercise | 25,000 | $N/A | $0 | |
| Feb 23, 2026 | Selecky Christobel | Executive | Sale | 25,000 | $10.00 | $250.0K | |
| Feb 23, 2026 | Selecky Christobel | Executive | Option Exercise | 25,000 | $2.98 | $74.5K | |
| Feb 22, 2026 | J. Simon Barry | Executive | Option Exercise | 15,243 | $N/A | $0 | |
| Feb 22, 2026 | J. Simon Barry | Executive | Payment | 6,026 | $8.70 | $52.4K | |
| Feb 22, 2026 | J. Simon Barry | Executive | Option Exercise | 15,243 | $N/A | $0 | |
| Feb 22, 2026 | Adcock Richard | Executive | Option Exercise | 152,439 | $N/A | $0 | |
| Feb 22, 2026 | Adcock Richard | Executive | Payment | 77,560 | $8.70 | $674.8K | Large |
| Feb 22, 2026 | Adcock Richard | Executive | Option Exercise | 152,439 | $N/A | $0 | |
| Feb 22, 2026 | J. Lauer Regan | Chief Accounting Officer | Option Exercise | 4,065 | $N/A | $0 | |
| Feb 22, 2026 | J. Lauer Regan | Chief Accounting Officer | Payment | 1,673 | $8.70 | $14.6K | |
| Feb 22, 2026 | J. Lauer Regan | Chief Accounting Officer | Option Exercise | 4,065 | $N/A | $0 | |
| Feb 22, 2026 | Soon-shiong Patrick | Executive | Option Exercise | 114,329 | $N/A | $0 | |
| Feb 22, 2026 | Soon-shiong Patrick | Executive | Payment | 58,170 | $8.70 | $506.1K | Large |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Other(J) | 7 | $103.4M | 61.4% |
Conversion(C) | 1 | $56.6M | 33.6% |
Sale(S) | 12 | $5.2M | 3.1% |
Payment(F) | 17 | $2.4M | 1.4% |
Exercise(M) | 39 | $397.7K | 0.2% |
Purchase(P) | 9 | $306.1K | 0.2% |
Gift(G) | 2 | $0 | 0.0% |
Insider selling pressure at ImmunityBio, Inc. has increased, with 13 insiders executing 87 transactions across all time. Total sales of $5.2M significantly outpace purchases of $306.1K, resulting in a net outflow of $4.9M. This selling activity appears largely discretionary, which may warrant closer attention from investors.